Raymond James Downgrades Zymeworks to Outperform, Announces $74 Price Target
Raymond James analyst David Novak downgrades Zymeworks (NYSE:ZYME) from Strong Buy to Outperform and announces $74 price target.
SVB Leerink Upgrades Zymeworks to Outperform
SVB Leerink analyst Andrew Berens upgrades Zymeworks (NYSE:ZYME) from Market Perform to Outperform.
SVB Leerink Maintains Market Perform on Zymeworks, Lowers Price Target to $27
SVB Leerink analyst Andrew Berens maintains Zymeworks (NYSE:ZYME) with a Market Perform and lowers the price target from $28 to $27.
Zymeworks’ Zanidatamab Aces Mid-Stage Esophageal Cancer Trial
At the European Society of Medical Oncology Congress 2021 (ESMO21), Zymeworks Inc (NYSE:ZYME) presented encouraging early data on…
HC Wainwright & Co. Maintains Buy on Zymeworks, Lowers Price Target to $44
HC Wainwright & Co. analyst Robert Burns maintains Zymeworks (NYSE:ZYME) with a Buy and lowers the price target from $55 to $44.
Zymeworks Q2 EPS $(1.31) Down From $(0.77) YoY, Sales $1.77M Down From $12.36M YoY
Zymeworks (NYSE:ZYME) reported quarterly losses of $(1.31) per share. This is a 70.13 percent decrease over losses of $(0.77) per share from the same period last year. The company reported $1.77 million in sales this
Zymeworks Shares Up 7.6%; Traders Circulate Street Insider Report ‘Zymeworks (ZYME) Explores Potential Sale Following Takeover Approach – Source’
https://www.streetinsider.com/Hot+M+and+A/Zymeworks+%28ZYME%29+Explores+Potential+Sale+Following+Takeover+Approach+-+Source/18633227.html?classic=1
Zymeworks Q1 EPS $(0.87) Down From $(0.64) YoY, Sales $644.00K Down From $8.27M YoY
Zymeworks (NYSE:ZYME) reported quarterly losses of $(0.87) per share. This is a 35.94 percent decrease over losses of $(0.64) per share from the same period last year. The company reported $644.00 thousand in sales this